Acadian Asset Management LLC Raises Holdings in United Therapeutics Corporation $UTHR

Acadian Asset Management LLC raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 15.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 206,018 shares of the biotechnology company’s stock after buying an additional 26,813 shares during the quarter. Acadian Asset Management LLC owned about 0.46% of United Therapeutics worth $59,173,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in UTHR. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics during the second quarter worth approximately $29,000. SVB Wealth LLC acquired a new position in United Therapeutics during the first quarter worth approximately $32,000. Geneos Wealth Management Inc. raised its position in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the period. Brooklyn Investment Group raised its holdings in shares of United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 98 shares during the period. Finally, WPG Advisers LLC purchased a new position in United Therapeutics in the first quarter valued at approximately $60,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $436.09, for a total value of $9,157,890.00. Following the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at $3,540,178.62. The trade was a 72.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 412,935 shares of company stock valued at $173,677,147 over the last quarter. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on UTHR. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Oppenheimer increased their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company upped their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, Bank of America raised their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $503.90.

United Therapeutics Trading Down 1.1%

UTHR stock opened at $448.91 on Monday. The firm has a market cap of $19.33 billion, a PE ratio of 17.01, a PEG ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $479.50. The company has a fifty day simple moving average of $423.96 and a 200 day simple moving average of $344.27.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the previous year, the company posted $6.39 earnings per share. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.